Data Readout

Alpha Tau's GBM device trial heads to a small feasibility readout in Q4 2026

A 10-patient feasibility study of the Alpha DaRT radiation seed in recurrent glioblastoma is recruiting toward a safety and placement readout, not an efficacy verdict.

By AppliedXLJuly 13, 2026Trial NCT06910306

Executive Summary

Alpha Tau is recruiting toward an initial feasibility and safety readout of its implantable alpha-radiation seed in patients with recurrent glioblastoma who cannot have surgery, with results guided for later this year.
The study is built to answer whether the device can be placed as intended and tolerated, not whether it shrinks tumors or extends survival, so the bar for this readout is operational and safety-based rather than a response-rate verdict.
No other program has tested an implanted alpha-emitter directly in glioblastoma, leaving Alpha Tau without a same-mechanism precedent to benchmark against, while several device and radiotherapy approaches are advancing in the same tumor type on different mechanisms.
The trial's timeline and design have stayed stable since the study opened, and the sponsor has repeated the same guided readout window twice, which supports treating the fourth-quarter timing as an operational commitment rather than a moving target.

The trial

The study, registered as NCT06910306, is enrolling adults with recurrent WHO grade IV glioblastoma whose tumors have progressed after standard radiation and chemotherapy and who are not candidates for surgical resection. It targets 10 patients and is recruiting in the United States, with a primary completion date of November 1, 2026 and full completion targeted for December 1, 2026. The trial tests implantation of Alpha DaRT seeds, an alpha-radiation-emitting device, directly into a single recurrent lesion no larger than 3 centimeters, in patients with a Karnofsky performance status of at least 60. NCT06910306

Probability of Success

Endpoint Met33%

Completes51%

Clinical Significance4%

Regulatory85%

What the readout will test

The registered primary endpoints are feasibility of DaRT seed placement and safety measured by adverse events, with overall survival, radiographic tumor control, pseudo-progression rate, and toxicity profile carried as secondary measures. That endpoint structure means the fourth-quarter data disclosure Alpha Tau has guided to will show whether the seeds can be implanted as planned and tolerated in this population, the necessary first step before any efficacy signal can be evaluated, not a response or survival result on its own. The company previously said it expected an initial safety readout from the first three patients in the second quarter of 2026, before consolidating guidance around the broader fourth-quarter window in its January 2026 shareholder letter. NCT06910306+1

Timing and stability

Alpha Tau has repeated the same October-to-December 2026 guided window in disclosures published January 29 and May 18, 2026, and the trial's primary completion date has not moved from November 1, 2026 since the study was first posted. The trial moved from "Not yet recruiting" to "Recruiting" status on December 5, 2025, and has recorded no protocol amendments to its endpoints, eligibility, or enrollment target since. The enrollment target itself has not changed since the study opened, holding at 10 patients, which sits within the routine band for a feasibility study of this size. Alpha+1

Competitive frame

No trial in glioblastoma or the wider CNS-tumor family currently tests an implanted alpha-emitting seed against a comparator, leaving Alpha Tau's device without a direct mechanism precedent in this indication. The closest points of reference are other localized radiation-delivery devices in the same tumor type, including GammaTile, a radiation-emitting surgical implant in a Phase 3 glioblastoma trial, and an early-phase lutetium-based radioligand tested by Novartis in glioblastoma, both of which deliver radiation locally but through different mechanisms and different device or drug forms. Beyond radiation-delivery devices, the broader glioblastoma field includes tumor-treating-field therapy, IDH-targeted small molecules, and gene-therapy approaches, none of which share Alpha Tau's alpha-particle mechanism. That absence of a same-mechanism comparator means the feasibility data Alpha Tau discloses this year will stand as the first read on whether an implanted alpha-emitter is deliverable in intracranial disease, without an existing outcome base rate to weigh it against. NCT07195591+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.